Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
$5.37
-1.1%		$5.14
$2.40
▼
$16.34
$201.90M1.3117,567 shs49,659 shs
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$3.21
-6.1%		$3.45
$1.90
▼
$8.21
$745.22M2.122.62 million shs2.17 million shs
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
$7.15
$7.67
$6.88
▼
$12.61
$757.63M1.221,829 shsN/A
Pharming Group NV stock logo
PHGUF
Pharming Group
$1.10
$1.23
$1.10
▼
$2.17
$738.18M0.46250 shsN/A
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
-1.10%+5.29%+17.51%-34.27%+120.08%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
-6.14%-2.13%+1.10%-10.83%+55.07%
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
0.00%+2.52%-10.63%-14.63%-2.72%
Pharming Group NV stock logo
PHGUF
Pharming Group
0.00%0.00%-15.38%-14.06%-15.38%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
$5.37
-1.1%		$5.14
$2.40
▼
$16.34
$201.90M1.3117,567 shs49,659 shs
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$3.21
-6.1%		$3.45
$1.90
▼
$8.21
$745.22M2.122.62 million shs2.17 million shs
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
$7.15
$7.67
$6.88
▼
$12.61
$757.63M1.221,829 shsN/A
Pharming Group NV stock logo
PHGUF
Pharming Group
$1.10
$1.23
$1.10
▼
$2.17
$738.18M0.46250 shsN/A
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
-1.10%+5.29%+17.51%-34.27%+120.08%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
-6.14%-2.13%+1.10%-10.83%+55.07%
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
0.00%+2.52%-10.63%-14.63%-2.72%
Pharming Group NV stock logo
PHGUF
Pharming Group
0.00%0.00%-15.38%-14.06%-15.38%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
2.67
Moderate Buy$15.00179.33% Upside
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
2.83
Moderate Buy$11.90270.72% Upside
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
2.00
HoldN/AN/A
Pharming Group NV stock logo
PHGUF
Pharming Group
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ARMP, OXBDF, PHGUF, and CTMX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/19/2026
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/13/2026
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$12.00 ➝ $11.00
8/10/2026
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$15.00 ➝ $14.00
7/22/2026
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
7/21/2026
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
6/16/2026
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
(Data available from 8/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
$4.90M40.75N/AN/A($6.22) per share-0.86
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$76.20M9.18N/AN/A$1.39 per share2.31
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
$164.59M4.60N/AN/A$0.62 per share11.53
Pharming Group NV stock logo
PHGUF
Pharming Group
$376.13M1.96$0.02 per share52.48$0.41 per share2.68
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
-$173.80M-$1.64N/AN/AN/A-3,467.04%-12.24%32.16%11/11/2026 (Estimated)
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
-$17.37M-$0.50N/AN/AN/A-435.21%-38.46%-30.33%11/5/2026 (Estimated)
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
-$46.74MN/AN/A55.00N/AN/AN/AN/AN/A
Pharming Group NV stock logo
PHGUF
Pharming Group
$2.85M$0.0191.67N/AN/A2.51%3.40%1.88%11/5/2026 (Estimated)

Latest ARMP, OXBDF, PHGUF, and CTMX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
-$0.4450-$0.27+$0.1750-$0.27$0.40 million$2.51 million
8/6/2026Q2 2026
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
-$0.0771-$0.09-$0.0129-$0.09$12.39 million$1.42 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
N/AN/AN/AN/AN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/AN/AN/AN/AN/A
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
N/AN/AN/AN/AN/A
Pharming Group NV stock logo
PHGUF
Pharming Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
N/A
0.11
0.11
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/A
9.36
9.36
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
N/AN/AN/A
Pharming Group NV stock logo
PHGUF
Pharming Group
0.40
2.63
2.06

Institutional Ownership

CompanyInstitutional Ownership
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
3.57%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
67.77%
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
N/A
Pharming Group NV stock logo
PHGUF
Pharming Group
N/A

Insider Ownership

CompanyInsider Ownership
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
84.50%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
3.80%
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
N/A
Pharming Group NV stock logo
PHGUF
Pharming Group
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
7037.18 million5.76 millionNot Optionable
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
170217.90 million209.62 millionOptionable
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
891105.96 millionN/ANot Optionable
Pharming Group NV stock logo
PHGUF
Pharming Group
382671.07 millionN/ANot Optionable

Recent News About These Companies

Pharming launches Joenja in Japan, first market to treat APDS children from age four
August 13, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/pharming-launches-joenja-in-japan-first-market-to-treat-apds-children-from-age-four?utm_source=marketbeat.com&utm_medium=referral
Pharming Group to Present at Canaccord Genuity Growth Conference
August 4, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/pharming-group-to-present-at-canaccord-genuity-growth-conference?utm_source=marketbeat.com&utm_medium=referral
Pharming Group Earnings Call: Growth Story Amid Pressure
July 30, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/pharming-group-earnings-call-growth-story-amid-pressure?utm_source=marketbeat.com&utm_medium=referral
Pharming Group (PHAR) Receives a Buy from Oppenheimer
June 28, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PHGUF/pressreleases/1826875/pharming-group-phar-receives-a-buy-from-oppenheimer/
Pharming Wins FDA Review for Joenja Pediatric sNDA in APDS
June 4, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/pharming-wins-fda-review-for-joenja-pediatric-snda-in-apds?utm_source=marketbeat.com&utm_medium=referral
Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS
June 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/04/3306506/0/en/pharming-announces-u-s-fda-acceptance-of-snda-resubmission-for-joenja-leniolisib-to-treat-children-aged-4-to-11-years-with-apds.html
Pharming Group appoints KPMG as new auditor as shareholders back full AGM agenda
May 28, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/pharming-group-appoints-kpmg-as-new-auditor-as-shareholders-back-full-agm-agenda?utm_source=marketbeat.com&utm_medium=referral
Pharming Wins EU Green Light for Joenja, First Approved Treatment for APDS
May 22, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/pharming-wins-eu-green-light-for-joenja-first-approved-treatment-for-apds?utm_source=marketbeat.com&utm_medium=referral
Pharming Group Balances Near-Term Strain With Joenja Growth
May 20, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/pharming-group-balances-near-term-strain-with-joenja-growth?utm_source=marketbeat.com&utm_medium=referral
Pharming Group Balances Short-Term Strain With Pipeline Gains
May 7, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/pharming-group-balances-short-term-strain-with-pipeline-gains?utm_source=marketbeat.com&utm_medium=referral
Pharming Group Showcases New Leniolisib Data and Expands Immunology Focus at CIS 2026
May 7, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/pharming-group-showcases-new-leniolisib-data-and-expands-immunology-focus-at-cis-2026?utm_source=marketbeat.com&utm_medium=referral
Pharming Group to report first quarter 2026 financial results and provide business update on May 7
April 23, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/pharming-group-report-first-quarter-060000385.html
Pharming Group N.V.: Pharming Group announces the 2026 Annual General Meeting of Shareholders
April 16, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-04/68213285-pharming-group-n-v-pharming-group-announces-the-2026-annual-general-meeting-of-shareholders-399.htm
Pharming Group Sets May 28, 2026 AGM With Key Governance and Capital Measures on Agenda
April 16, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/pharming-group-sets-may-28-2026-agm-with-key-governance-and-capital-measures-on-agenda?utm_source=marketbeat.com&utm_medium=referral
Canaccord Genuity initiates coverage of Pharming Group NV - Depositary Receipt (PHAR) with buy recommendation
April 11, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/canaccord-genuity-initiates-coverage-of-pharming-group-nv-depositary-receipt-phar-with-buy-recommendation/ar-AA20DlEx
Pharming Group Files 2025 Annual Report and Form 20-F
April 2, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/pharming-group-files-2025-annual-report-and-form-20-f?utm_source=marketbeat.com&utm_medium=referral
Pharming Group announces the filing of its 2025 Annual Report and Form 20-F
April 2, 2026  |  manilatimes.netM
Pharming Group Wins Positive EMA Panel Backing for Joenja in Rare APDS
March 27, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/pharming-group-wins-positive-ema-panel-backing-for-joenja-in-rare-apds?utm_source=marketbeat.com&utm_medium=referral
Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older
March 27, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/pharming-group-receives-positive-chmp-060000198.html
We Think Pharming Group's (AMS:PHARM) Robust Earnings Are Conservative
March 25, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/think-pharming-groups-ams-pharm-052100272.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Armata Pharmaceuticals stock logo

Armata Pharmaceuticals NYSEAMERICAN:ARMP

$5.37 -0.06 (-1.10%)
As of 08/28/2026 04:10 PM Eastern

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.

CytomX Therapeutics stock logo

CytomX Therapeutics NASDAQ:CTMX

$3.21 -0.21 (-6.14%)
As of 08/28/2026 04:00 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Oxford BioMedica stock logo

Oxford BioMedica OTCMKTS:OXBDF

$7.15 0.00 (0.00%)
As of 08/27/2026

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

Pharming Group stock logo

Pharming Group OTCMKTS:PHGUF

$1.10 0.00 (0.00%)
As of 08/27/2026

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas